Relapsed/refractory AML
Clinical trials for Relapsed/refractory AML explained in plain language.
Never miss a new study
Get alerted when new Relapsed/refractory AML trials appear
Sign up with your email to follow new studies for Relapsed/refractory AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they'r…
Matched conditions: RELAPSED/REFRACTORY AML
Phase 1 • Sponsor: Auron Therapeutics, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for AML patients who fail venetoclax?
Disease control Recruiting nowThis pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…
Matched conditions: RELAPSED/REFRACTORY AML
Phase 2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC